March 13, 2020
As the coronavirus epidemic prompts cancellations of scientific meetings around the world, we have been working on alternative methods to keep you informed of advances in 3D cell-based assay technology, […]
February 26, 2020
InSphero Oncology Experts Francesca Chiovaro and Irina Agarkova often collaborate closely with academic and pharma partners who are developing therapeutics that target the innate immune system. In this blog, Francesca shares […]
December 18, 2019
InSphero CEO Jan Lichtenberg muses about how far 3D cell technology has come since InSphero was founded in 2009 and shares the latest news about how our disruptive 3D technology […]
September 23, 2019
Model systems, whether laboratory animals or human cell-based systems, have long been central to the discovery and development of new and better drugs for the treatment of human disease. But […]
July 30, 2019
InSphero Senior Application Scientist Sue Grepper explains why critical limitations of dietary and genetically modified rodent models for NASH may be slowing down drug discovery efforts in this blog. She […]
July 17, 2019
InSphero CEO Jan Lichtenberg and renowned liver disease expert Dr. Scott Friedman of the Icahn School of Medicine at Mount Sinai recently talked to PharmaExec magazine about how to resolve […]
July 11, 2019
InSphero’s Akura™ technology platforms team worked with Professor Andreas Hierlemann’s Bioengineering Laboratory at ETH Zürich to develop a microfluidic hanging drop system to assess metabolic competence in developmental toxicity assays. […]
July 10, 2019
InSphero CEO Jan Lichtenberg reflects on ADA2019 and how InSphero is enabling T1D and T2D Discovery with our 3D InSight™ Diabetes Discovery Platform. Over the past few years, diabetes discovery […]
September 28, 2018
Microfluidic chips enable researchers to manipulate, image, and analyze small tissue constructs under optimal culturing conditions. Microfluidics, the technology behind emerging #body-on-a-chip and #organs-on-chips systems, is poised to transform the […]
August 20, 2018
Pharma companies racing to develop new drugs to combat chronic liver diseases, such as NASH and fibrosis, need better preclinical testing tools for compound screening and mechanistic studies. Here’s how […]